Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis.
Pennati
Marzia
M
Colella
Gennaro
G
Folini
Marco
M
Citti
Lorenzo
L
Daidone
Maria Grazia
MG
Zaffaroni
Nadia
N
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism; D002868:Chromosomal Proteins, Non-Histone / Q000235:genetics*; D002945:Cisplatin / Q000494:pharmacology; D015853:Cysteine Proteinase Inhibitors; D015870:Gene Expression; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008545:Melanoma; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D016337:RNA, Catalytic / Q000235:genetics / Q000378:metabolism*; D000077022:Survivin; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; C107489:BIRC5 protein, human; D002868:Chromosomal Proteins, Non-Histone; D015853:Cysteine Proteinase Inhibitors; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D016337:RNA, Catalytic; D000077022:Survivin; C427204:hammerhead ribozyme; C505407:CASP3 protein, human; D053148:Caspase 3; D020169:Caspases; D002945:Cisplatin